Pura Scents recalling more than 850,000 diffusers as magnet issue may cause ingestion hazard
The company is recalling about 851,400 Pura 4 Smart Home Fragrance Diffusers with detachable covers. It said an additional 1,100 were sold in Canada.
Pura Scents said that the magnets on the inside cover of the product can detach, posing an ingestion hazard to children. When high-powered magnets are swallowed, the ingested magnets can attract each other, or other metal objects, and become lodged in the digestive system. This can result in perforations, twisting or blockage of the intestines, infection, blood poisoning and death.
The company has received three reports of magnets detaching from the cover. No injuries have been reported.
The diffusers were sold at Target, Scheels and other stores nationwide from August 2023 through May 2025 for about US$50. They were also sold online through Pura's website, as well as online at Amazon, Target and Scheels.
Pura Scents is offering a free replacement cover. Consumers are advised to immediately dispose of the existing detachable cover and to keep the diffusers out of the reach of children and pets.
To receive the free replacement cover, individuals may contact Pura Scents at 855-394-5292 from 9 a.m. to 5 p.m. MT Monday through Friday. The company can also be emailed at replacement@pura.com. Consumers may also visit the company's website and click on 'Recall' at the bottom of the page for more information.
Michelle Chapman, The Associated Press
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
18 minutes ago
- Globe and Mail
Canada is hosting the world's biggest dementia conference for the first time in a decade. What's changed since then?
This week, researchers from around the globe are descending upon downtown Toronto to attend the Alzheimer's Association International Conference, the world's biggest and most influential meeting for dementia research. The gathering is a chance for the international dementia community to discuss the latest research in the field; it's also where significant breakthroughs are often unveiled. At a related event on Saturday, the Canadian Institutes of Health Research (CIHR) – Canada's health research funding agency – announced $44.8-million in new funding for dementia and aging-related research initiatives, including the creation of 16 teams that will study everything from Alzheimer's biomarkers to dementia in Indigenous populations. To set the stage for this year's conference, The Globe and Mail checked in with Jane Rylett, a professor at Western University and scientific director at the CIHR Institute of Aging, which hosted Saturday's event. The last time this global conference was held in Canada was in 2016, nearly a decade ago. How has the dementia research landscape changed since then? This is a really important inflection point. There is a new class of drugs, the antibody therapy, that came into the market within the last three or four years; they probably will be approved in Canada in the coming years. But while there's huge hope around it . . . right now, there's a lot of debate around if they're really beneficial. For certain people, they don't work at all; other people have negative side effects by creating inflammation in the brain. And the benefit-to-risk ratio is not great. So I think at this year's conference, it's going to be really important to hear about new findings with that. Something that's really gained momentum over the last few years is stepping back from the pharmacological approach to treatment and saying, 'What else can we do that will reduce the risk of developing dementia?' Health system urged to brace for major shift in dementia demographics The other thing that's changed is there's always been an 'amyloid hypothesis' of Alzheimer's disease, based on these toxic peptides that get made in the brain and clearly have a role in brain health and development of dementia. But during these nine years, there's been a much greater move towards understanding the role of those and recognizing that while they're still important, they're not the whole story. Now there's more openness to looking at other hypotheses about how brain health can be impacted during the life course and can lead to dementia. How should people feel about this present moment? Thinking back to 2012, the United States' health department set an ambitious goal to prevent and effectively treat Alzheimer's disease by 2025. But here we are today and that goal is far from met. When people or groups make those kinds of statements, it doesn't necessarily mesh with the complication of the thing. And then what happens is people see [the missed deadline] and think, well, it didn't happen. That's always the danger of doing something like that. The brain is a complex thing, it really is. The problem with something like Alzheimer's disease is it's so multi-faceted and it's a spectrum. There's so many areas of the brain that are impacted and the clinical presentation can look similar for people but what's happening in their brain, and where the degeneration is initiated, can be quite different. There's no one pill that you're going to have that's going to be able to change the course or alleviate the symptoms. So was it realistic to say in 2012 that this could be cured by 2025? Probably not. But it stimulated a lot of activity. We understand much more about the underlying pathology and the pathogenesis of the disease. And stepping back was an important thing, saying what can we do that is not a pharmaceutical or a pill? What are the life, behavioural and other things that we can do? Canada has a chance to change the Alzheimer's experience - let's not squander it There's been a lot of focus on the funding cuts in the U.S. that are under way right now, including to the National Institutes of Health (NIH). How has that affected things? is it looming over the conference this year? Yes. A number of Canadian researchers also have been funded by NIH, either in their own right or as subcontracts on larger studies within the U.S., and for the most part, that has been ended, which is very problematic. So we have a number of very good Canadian researchers in all fields that have lost substantial funding, and we don't have the resources in Canada to replace that. One of the big question marks is the impact it's going to have on the number of Americans that are going to be able to attend the conference. And I don't know the answer to that yet. Let's talk about Canadian researchers. What role are they playing within the broader effort? Canadian researchers are leaders internationally in these fields of study. There's really significant work being done by Canadians in the biomarkers area, so the diagnostic area. We have a lot of expertise around how to develop and promote new methods for supporting caregivers and persons with dementia. Alzheimer's trial brings at-risk patients hope for the future, but new doubts in the present We've got outstanding Indigenous cognitive health researchers that are developing new culturally safe and appropriate diagnostic and caregiving methods. And we do have some very good work going on around pathogenesis, looking at changes in the brain during aging and how that may lead to loss of cognition. That's important because you really need to understand where those earliest changes come from. Those are the targets where you need to develop drugs and therapies. This interview has been edited and condensed.
Globe and Mail
18 minutes ago
- Globe and Mail
AstraZeneca's AZD4144 Study Completion: Key Insights for Investors
AstraZeneca ((AZN)), Parexel International ((PRXL)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. AstraZeneca, in collaboration with Parexel International, recently completed a Phase I clinical study titled An Open-label, Randomised, 2-arm, 3-period, 6-treatment Single-dose, Crossover Study Comparing the Pharmacokinetics of 2 Different Formulations of AZD4144, and Effect of Food and Omeprazole on the Pharmacokinetics of AZD4144 in Healthy Participants. The study aimed to evaluate the pharmacokinetics of two formulations of AZD4144 and the impact of food and omeprazole on its absorption in healthy individuals. The study tested two formulations of AZD4144, an investigational drug, in tablet and oral solution forms. It also assessed the effect of omeprazole, a commonly used medication for reducing stomach acid, on AZD4144's pharmacokinetics. This open-label, randomized, crossover study involved two arms with different treatment sequences. Participants received single doses of AZD4144 under various conditions, including fasted and fed states, and in combination with omeprazole. The primary goal was to understand how these factors influence the drug's absorption and processing in the body. The study commenced on April 23, 2025, and was completed by July 22, 2025. These dates are crucial as they mark the timeline of the study's execution and data collection, which can affect the timing of subsequent phases and regulatory submissions. This update could influence AstraZeneca's stock performance by providing insights into the drug's development progress. Positive results might boost investor confidence, while any setbacks could have the opposite effect. The study's completion also positions AstraZeneca competitively within the pharmaceutical industry as it advances its pipeline. The study is now completed, with further details available on the ClinicalTrials portal.
CTV News
18 minutes ago
- CTV News
Drug warning issued in North Bay area
Police in North Bay are issuing a high-priority safety alert after a recent probe of an overdose uncovered two extremely dangerous drugs. Eric Taschner has more.
